NCT06668584 2026-03-04A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid MalignanciesM.D. Anderson Cancer CenterPhase 2 Recruiting31 enrolled